bendamustine

November 22, 2019November 22, 2019

EU Advisory Committee Favors Approval of Polivy with MabThera and Bendamustine for Advanced DLBCL

News

An advisory committee for the European Medicines Agency has recommended the conditional approval of Roche‘s Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) and bendamustine (a chemotherapy) for the treatment of ... Read more

February 27, 2019

FDA Grants Priority Review to Polatuzumab Vedotin Combo for Difficult-to-treat DLBCL

News

The U.S. Food and Drug Administration has granted priority review to Roche‘s polatuzumab vedotin in combination with Rituxan (rituximab) and the chemotherapy bendamustine for the treatment of patients with relapsed or refractory ... Read more

September 4, 2018

Penn’s Abramson Cancer Center Added as Second Clinical Trial Site for CPI-613 in T-cell Lymphoma

News

The Abramson Cancer Center at the University of Pennsylvania will serve as a second trial site in the Phase 1 study of CPI-613 for T-cell lymphoma patients, according to Rafael Pharmaceuticals, the drug’s developer. The ... Read more

August 2, 2018

Venclexta Triple Combo in NHL Patients Produces Long-lasting Responses in Phase 1 Trial

News

A combination of Venclexta (venetoclax), bendamustine, and Rituxan (rituximab) is tolerable and produces long-lasting responses in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), according to a Phase 1 trial. The study, “Venetoclax, bendamustine, ... Read more

May 29, 2018

Arzerra-Bendamustine Combo Fails to Delay Disease Worsening in Indolent Non-Hodgkin’s Lymphoma Patients in Phase 3 Trial

News

Adding Arzerra (ofatumumab) to the chemotherapy agent bendamustine did not delay disease progression or death in indolent non-Hodgkin’s lymphoma patients whose disease failed to respond to Rituxan (rituximab) treatment, according to a ... Read more

March 27, 2018

Venclexta-Rituxan Combo Reduced Disease Progression in Relapsed CLL Patients in Phase 3 Trial

News

A combination of Venclexta (venetoclax) and Rituxan (rituximab) significantly reduces the risk of disease progression or death in relapsed or refractory chronic lymphocytic leukemia (CLL) patients, according to a Phase 3 clinical ... Read more

December 7, 2017

Polatuzumab Vedotin Addition Makes Stark Difference for DLBCL Patients, Studies Show

News

Adding the investigational treatment polatuzumab vedotin to a therapy of Bendeka (bendamustine) and Rituxan (rituximab) made patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) respond better to the ... Read more

February 10, 2017February 10, 2017

Canada OKs Gazyva-based Therapy for Follicular Lymphoma When Rituxan Fails

News

Canada’s medical regulatory agency has approved a Gazyva-based combo therapy for follicular lymphoma patients whose disease progressed either while or after they were treated with a Rituxan-based regimen. The therapy ... Read more

August 24, 2016August 24, 2016

Chemo Mix Using Treanda Before HSCT Seen of Benefit in Phase 2 Study

News

According to the results of a Phase 2 clinical trial, the triple combination of Treanda (bendamustine), Gemzar (gemcitabine), and Navelbine (vinorelbine) effectively induced complete remission in a large percentage of ... Read more

August 18, 2016August 18, 2016

Gazyva Combination Effective Therapy for NHL Patients Refractory to Rituxan

News

Results from the Phase 3 GADOLIN trial reveal that combining Gazyva (obinutuzumab) with bendamustine (available as Bendeka and Treanda) in patients with indolent non-Hodgkin’s lymphoma who are not responding to ... Read more